

# Min Y Teo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8383581/publications.pdf>

Version: 2024-02-01

62  
papers

2,178  
citations

566801

15  
h-index

243296

44  
g-index

66  
all docs

66  
docs citations

66  
times ranked

3668  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 69-79.	0.9	2
2	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	0.8	42
3	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
4	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 431-441.	0.9	5
5	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	1.5	6
6	Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2021, 44, 248-253.	1.2	10
7	<i>NECTIN4</i> Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibodyâ€Drug Conjugate. <i>Clinical Cancer Research</i> , 2021, 27, 4950-4952.	3.2	5
8	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.2	2
9	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 1214-1221.	2.9	14
10	A phase II trial of durvalumab and tremelimumab in metastatic, nonâ€urothelial carcinoma of the urinary tract. <i>Cancer Medicine</i> , 2021, 10, 1074-1083.	1.3	10
11	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 907-915.	0.9	21
12	DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.		37
13	Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1623-1630.	2.3	12
14	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417
15	The landscape of immunotherapy in metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2019, 29, 643-648.	0.9	5
16	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. <i>American Journal of Surgical Pathology</i> , 2019, 43, 920-927.	2.1	59
17	Refining existing knowledge and management of bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 75-76.	1.9	3
18	Genomic Differences Between â€œPrimaryâ€ and â€œSecondaryâ€ Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. <i>European Urology</i> , 2019, 75, 231-239.	0.9	104

#	ARTICLE	IF	CITATIONS
19	A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2019, 37, 4559-4559.	0.8	1
20	Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).. Journal of Clinical Oncology, 2019, 37, 551-551.	0.8	8
21	Metacure: Multi-arm multimodality therapy for very high risk localized and low volume metastatic prostatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS349-TPS349.	0.8	3
22	Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, 227-227.	0.8	1
23	Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration.. Journal of Clinical Oncology, 2019, 37, 443-443.	0.8	0
24	Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?. Journal of Clinical Oncology, 2019, 37, 459-459.	0.8	0
25	Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI).. Journal of Clinical Oncology, 2019, 37, e16035-e16035.	0.8	0
26	Treatment sequencing of anti-PD-1/PD-L1 and carboplatin (carbo)-based chemotherapy (chemo) in cisplatin-ineligible patients (pts) with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2019, 37, 4541-4541.	0.8	0
27	Abstract CT179: ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma. , 2019, , .		1
28	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 287-295.	0.8	10
29	Nivolumab for the treatment of urothelial cancers. Expert Review of Anticancer Therapy, 2018, 18, 215-221.	1.1	18
30	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology, 2018, 15, 168-182.	12.5	7
31	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	0.8	399
32	Reply to S. Zhang et al. Journal of Clinical Oncology, 2018, 36, 3057-3058.	0.8	1
33	Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). British Journal of Cancer, 2018, 119, 1041-1043.	2.9	4
34	EMA and FDA prune the checkpoint inhibitor treatment landscape. Nature Reviews Urology, 2018, 15, 596-597.	1.9	8
35	First-line PD-1/PD-L1 inhibitor followed by carboplatin (carbo)-based chemotherapy (chemo) or the reverse sequence in cisplatin-ineligible metastatic urothelial cancer (mUC) patients (pts).. Journal of Clinical Oncology, 2018, 36, e16517-e16517.	0.8	3
36	Defining the DNA damage repair (DDR) genomic landscape of urothelial carcinoma of the bladder (UCB).. Journal of Clinical Oncology, 2018, 36, 502-502.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC).. Journal of Clinical Oncology, 2018, 36, 522-522.	0.8	3
38	Synthetic Lethality: Achilles Heel in Select Patient Subpopulations. , 2018, , 257-270.		0
39	Next generation sequencing of urothelial bladder cancer: Memorial Sloan Kettering Cancer Center experience in 454 patients.. Journal of Clinical Oncology, 2018, 36, 469-469.	0.8	3
40	Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 47-52.	0.6	82
41	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	3.2	225
42	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 2017, 77, 1035-1046.	0.4	15
43	P2.01-066 PD-L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S827.	0.5	0
44	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications, 2017, 8, 2193.	5.8	99
45	Evaluation of a multimodal strategy to accelerate drug evaluations in early-stage metastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 187-187.	0.8	0
46	Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. Journal of Gastrointestinal Oncology, 2016, 7, 738-749.	0.6	14
47	Insomnia prevalence in an oncology patient population: an Irish tertiary referral centre experience. Annals of Oncology, 2016, 27, vi520.	0.6	0
48	Prostate-Specific Membrane Antigen-Targeted Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2016, 22, 347-352.	1.0	11
49	CHAARTED/GETUG 12 docetaxel in non-castrate prostate cancers. Nature Reviews Clinical Oncology, 2015, 12, 687-688.	12.5	4
50	Benefit of chemotherapy (ctx) in elderly patients (pts) with advanced pancreatic adenocarcinoma (PC): A population-based analysis.. Journal of Clinical Oncology, 2014, 32, 310-310.	0.8	3
51	Does interval from histologic diagnosis (Dx) to start of chemotherapy (Ctx) impact survival in metastatic colorectal cancer (MCRC)?. Journal of Clinical Oncology, 2014, 32, 615-615.	0.8	0
52	Response to second-line chemotherapy (Ctx) in advanced urothelial carcinoma: A pooled retrospective analysis of the correlation between objective response rate (ORR) and progression-free survival (PFS) and overall survival (OS).. Journal of Clinical Oncology, 2014, 32, 354-354.	0.8	0
53	Active surveillance of pulmonary metastases in renal cancer patients.. Journal of Clinical Oncology, 2014, 32, 445-445.	0.8	4
54	Identification of Distinct Phenotypes of Locally Advanced Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer, 2013, 44, 73-78.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Beyond the Maths of Biology: Long-term Spontaneous Tumoral Regression After Sunitinib Withdrawal. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 198-200.	0.9	1
56	The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2013, 114, 149-154.	1.4	179
57	A case of sarcoidosis in a patient with testicular cancer post stem cell transplant. <i>Acta Oncologica</i> , 2013, 52, 869-870.	0.8	7
58	Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1215-1221.	0.5	35
59	Doublet Chemotherapy in the Elderly Patient With Ovarian Cancer. <i>Oncologist</i> , 2012, 17, 1450-1460.	1.9	11
60	Seminoma and sarcoid: A confusing collision.. <i>Journal of Clinical Oncology</i> , 2012, 30, 339-339.	0.8	1
61	<i>NUT</i> Midline Carcinoma in a Young Woman. <i>Journal of Clinical Oncology</i> , 2011, 29, e336-e339.	0.8	27
62	A Case of Metastatic Renal Cell Cancer Presenting as Jaundice. <i>World Journal of Oncology</i> , 2010, 1, 218-220.	0.6	5